Contents
A laboratory result usually answers a straightforward question: How much of a substance is present? A biomarker ratio asks a second question: How does that result relate to another part of the same biological system?
For example, cholesterol ratios compare cholesterol carried in different lipoproteins. The AST-to-ALT ratio compares two enzymes released through overlapping but different pathways. The urine albumin-to-creatinine ratio adjusts urine albumin for urine concentration. Percent-free PSA compares two forms of prostate-specific antigen to refine prostate-risk assessment.
This relational view can reveal a pattern that is harder to recognize from one number alone. It can also mislead when the wrong formula, units, cutoff, or clinical context is used. Some ratios—such as urine albumin-to-creatinine ratio, FIB-4, transferrin saturation, and the aldosterone-to-renin ratio—have defined roles in clinical guidance. Others remain supportive, disease-specific, or primarily research tools.
Ulta Lab Tests provides direct online access to many of the component tests discussed below where available. Laboratory testing supplies objective health information, but a ratio does not diagnose a condition by itself and should not replace evaluation by a qualified healthcare professional.
Direct answer: A biomarker ratio is a calculated value that compares two laboratory measurements or combines several measurements in one formula. It may help describe balance, relative excess, filtration, transport, inflammation, or disease probability more clearly than either component alone.
Most ratios use one of three structures:
LDL cholesterol ÷ HDL cholesterol(Free PSA ÷ Total PSA) × 100FIB-4 = (Age × AST) ÷ (Platelets × √ALT)Some valuable related ratios are not strictly blood based. The urine albumin-to-creatinine ratio uses a spot urine sample, while PSA density combines a blood PSA result with prostate volume measured through imaging.
Suppose a person has an elevated triglyceride-to-HDL ratio. That could reflect elevated triglycerides, low HDL cholesterol, a combination of both, a nonfasting sample, recent alcohol intake, acute illness, medication effects, or differences in metabolic background.
The same logic applies throughout laboratory medicine. A high neutrophil-to-lymphocyte ratio could result from neutrophilia, lymphopenia, or both. A high BUN-to-creatinine ratio could arise from increased BUN, unusually low creatinine, or a combination. A ratio should therefore never be read without its numerator and denominator.
Ratios can add value in four main ways.
An absolute marker may be affected by concentration, body size, muscle mass, binding proteins, or another biological variable. Ratios can sometimes adjust for that influence. uACR, for example, relates urine albumin to urine creatinine so a dilute or concentrated spot urine sample can be interpreted more meaningfully.
LDL cholesterol measures cholesterol mass within LDL particles, whereas apolipoprotein B reflects the number of atherogenic particles. A person can have an LDL-C result that appears relatively controlled while still having an unexpectedly high number of ApoB-containing particles. Cardiovascular guidance identifies ApoB as especially useful in people with elevated triglycerides, diabetes, metabolic syndrome, or low achieved LDL-C.1
Liver fibrosis indices combine markers of cellular injury with platelet count and, in the case of FIB-4, age. This produces a risk estimate that is more informative for fibrosis triage than AST or ALT alone.
A ratio that changes consistently under comparable testing conditions may help a clinician judge whether a physiological pattern is improving, worsening, or remaining stable. A trend is still not proof of cause, and a changing denominator can make the ratio move even when the numerator remains unchanged.
| Symptom or risk factor | What it may suggest | Tests that may provide more information |
|---|---|---|
| Family history of premature cardiovascular disease, diabetes, or abnormal cholesterol | Possible inherited or metabolic cardiovascular risk | Lipid Panel Test with Ratios, Apolipoprotein A1 and B Test, Glucose Test, and A1c Test |
| High blood pressure, elevated waist circumference, or high triglycerides | Cardiometabolic risk pattern | Lipid Panel Test with Ratios, Glucose Test, A1c Test, Comprehensive Metabolic Panel Test, and Albumin Random Urine Test with Creatinine |
| Persistently abnormal liver enzymes or liver fat seen on imaging | Liver injury or possible fibrosis risk | Comprehensive Metabolic Panel Test and Complete Blood Count with Differential and Platelets for FIB-4 components; clinician-directed imaging may also be appropriate |
| Diabetes, hypertension, cardiovascular disease, or family history of kidney disease | Increased risk of albuminuria or reduced filtration | Kidney Profile, Albumin Random Urine Test with Creatinine, and Cystatin C Test with eGFR when appropriate |
| Fatigue, pallor, shortness of breath with exertion, or restless legs | Possible anemia or altered iron availability | Complete Blood Count with Differential and Platelets and Ferritin, Iron and Total Iron Binding Capacity Panel |
| Difficult-to-control hypertension or low potassium | Possible secondary cause of hypertension | Comprehensive Metabolic Panel Test and clinician-directed Aldosterone and Plasma Renin Activity Ratio Test |
| Fever, infection symptoms, inflammatory illness, or treatment monitoring | Change in immune-cell balance or acute-phase proteins | Complete Blood Count with Differential and Platelets and hs-CRP Test when appropriate |
| Borderline total PSA or a change in PSA pattern | Need for additional prostate-risk context | PSA Free and Total Test; urologic evaluation and imaging may also be appropriate |
Safety note: Seek urgent medical care for chest pain, sudden shortness of breath, stroke-like symptoms, confusion, fainting, vomiting blood, black stools, severe jaundice, markedly reduced urine output, or other sudden and severe symptoms. Direct-access testing should not delay emergency evaluation.
Lab tests can help quantify biomarkers, reveal patterns, establish a baseline, and monitor change. They cannot, by themselves, explain every cause of an abnormal result.
A ratio cannot determine whether an abnormality comes from diet, genetics, medication, infection, organ disease, strenuous exercise, hydration status, or another factor. Even a validated score such as FIB-4 is a risk-stratification tool, not a biopsy result. A high value may indicate that further assessment is appropriate; it does not prove that advanced fibrosis is present.
Cardiovascular assessment relies on overall atherosclerotic cardiovascular disease risk together with absolute LDL-C, non-HDL-C, triglycerides, and selected advanced markers such as ApoB. Cholesterol ratios may provide supporting context, but they should not be used as stand-alone treatment targets. HDL-C should also not be interpreted by itself.1
| Ratio | Formula | What it may show | Clinical status and limitations |
|---|---|---|---|
| Total cholesterol/HDL-C | Total cholesterol ÷ HDL-C | Overall cholesterol burden relative to HDL-C | Commonly reported and useful as supporting context; not a stand-alone treatment target |
| LDL-C/HDL-C | LDL-C ÷ HDL-C | LDL cholesterol relative to HDL-C | Easy to calculate, but can obscure absolute LDL-C, non-HDL-C, ApoB, Lp(a), and total risk |
| Triglycerides/HDL-C | Triglycerides ÷ HDL-C | A lipid pattern often associated with insulin resistance and metabolic risk | Research-supported surrogate; not a diagnostic test and lacks a universal cutoff |
| ApoB/ApoA1 | ApoB ÷ ApoA1, using the same units | Atherogenic particle burden relative to the major HDL-associated apolipoprotein | Potentially useful in discordant lipid patterns; absolute ApoB is more directly incorporated into current guidance |
A higher TG-to-HDL ratio is associated with insulin resistance and cardiometabolic risk in many studies. However, proposed cutoffs differ by sex, age, ethnicity, weight, fasting status, and unit system. The ratio has also performed poorly in some populations. It should be interpreted with the Glucose Test, A1c Test, blood pressure, waist measurement, and the complete Lipid Panel Test with Ratios rather than being used to diagnose insulin resistance.2
Unit warning: A TG-to-HDL result calculated in mg/dL is not numerically interchangeable with one calculated in mmol/L because triglycerides and cholesterol use different conversion factors.
ApoB reflects atherogenic particles because each LDL, VLDL, IDL, and Lp(a) particle contains an ApoB molecule. ApoA1 is the primary structural apolipoprotein in HDL. Their ratio can describe particle balance, but clinicians increasingly focus on the absolute ApoB concentration when residual particle-related risk is suspected. The Apolipoprotein A1 and B Test supplies both components.3
Blood-cell and protein-derived ratios are attractive because they can often be calculated from tests already obtained. Their major limitation is that proposed thresholds are highly dependent on the condition being studied.
| Ratio or index | Formula | What it reflects | Important limitation |
|---|---|---|---|
| Neutrophil-to-lymphocyte ratio, NLR | Absolute neutrophils ÷ absolute lymphocytes | Relative shift between innate and adaptive immune-cell counts | Infection, stress, steroids, smoking, cancer, surgery, and many other factors can alter it |
| Platelet-to-lymphocyte ratio, PLR | Platelets ÷ absolute lymphocytes | Platelet activation or thrombocytosis relative to lymphocyte count | Mostly studied as a disease-specific prognostic marker |
| Systemic Immune-Inflammation Index, SII | Platelets × neutrophils ÷ lymphocytes | Composite cell-count inflammatory pattern | Not standardized for general screening |
| CRP-to-albumin ratio, CAR | CRP ÷ albumin | Rising acute-phase response relative to falling albumin | Units and disease-specific cutoffs vary substantially |
| RDW-to-platelet ratio | RDW ÷ platelets, sometimes multiplied by a scale factor | Red-cell size variability relative to platelets | Formula and scaling differ across publications |
One study of healthy, non-geriatric adults reported an NLR range of approximately 0.78 to 3.53. That is not a universal diagnostic interval: age, ancestry, pregnancy, illness, laboratory method, medications, and the clinical setting can shift the expected value.4
CAR, PLR, SII, and related ratios are used mainly in research and condition-specific hospital or oncology settings. Published CAR cutoffs, for example, vary according to whether the study concerns intensive care, surgery, kidney disease, cancer, or inflammatory bowel disease. A single red-or-green consumer cutoff would create false certainty. The underlying components may be obtained from the Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel Test, and selected inflammatory testing such as the hs-CRP Test.
AST/ALT ratio = AST ÷ ALT
ALT is more concentrated in the liver, while AST is also found in skeletal muscle, heart, and other tissues. An AST-to-ALT ratio above 2 can support suspicion for alcohol-associated liver disease in an appropriate clinical context, but it is not diagnostic. AST greater than ALT can also occur in cirrhosis from other causes, muscle injury, and other conditions. Normal AST and ALT do not exclude metabolic dysfunction-associated steatotic liver disease.5
FIB-4 = (Age × AST) ÷ [Platelet count × √ALT]
Use age in years, AST and ALT in U/L, and platelet count in 109/L.
FIB-4 is less reliable in people younger than 35 or older than 65, and age-adjusted interpretation may be needed. Acute illness, platelet disorders, alcohol exposure, and non-liver sources of AST can also alter the score.6
APRI = [(AST ÷ laboratory AST upper limit of normal) ÷ Platelet count] × 100
Platelets are entered in 109/L. In its chronic hepatitis B guidance, the World Health Organization uses an APRI above 0.5 as evidence supporting significant fibrosis and above 1.0 as supporting cirrhosis in a defined hepatitis B and resource-limited setting. Those values should not be applied as universal cutoffs for every liver disorder. Transient elastography or another secondary test may be preferable when available.7
Clinical perspective: FIB-4 and APRI are triage tools. They help identify who may benefit from additional testing; they do not establish the cause of liver injury or replace imaging, elastography, specialist evaluation, or biopsy when those are needed. The Comprehensive Metabolic Panel Test and Complete Blood Count with Differential and Platelets provide the principal laboratory components.
The urine albumin-to-creatinine ratio, or uACR, relates albumin loss to urine creatinine concentration. Laboratories normally perform the required unit conversion and report the result in mg/g.
| uACR | Category | General meaning |
|---|---|---|
| Below 30 mg/g | A1 | Normal to mildly increased |
| 30–300 mg/g | A2 | Moderately increased |
| Above 300 mg/g | A3 | Severely increased |
Albuminuria and eGFR are interpreted together because each contributes independent information about kidney and cardiovascular risk. An elevated result is generally repeated to confirm persistence, often within three to six months depending on the clinical situation. Exercise, fever, infection, menstruation, marked hyperglycemia, and short-term blood-pressure changes can temporarily increase albumin excretion.8
The Kidney Profile combines creatinine-based filtration information with urine albumin testing. The standalone Albumin Random Urine Test with Creatinine supplies the urine components used for uACR.
BUN/creatinine ratio = BUN (mg/dL) ÷ creatinine (mg/dL)
A disproportionately high BUN relative to creatinine may be seen with reduced kidney perfusion, dehydration, gastrointestinal bleeding, increased protein breakdown, corticosteroid use, or high protein intake. However, BUN is affected by many non-kidney factors, making this ratio suggestive rather than conclusive. A low creatinine caused by low muscle mass can also make the ratio appear high.9
Creatinine is influenced by muscle mass, diet, and some medications. Cystatin C has a different set of non-kidney influences. Rather than relying on a homemade creatinine-to-cystatin-C ratio or an eGFRcys-to-eGFRcreat cutoff, current kidney guidance recommends the combined creatinine-cystatin C eGFR equation when cystatin C is available. The combined estimate is usually more accurate, especially when creatinine- and cystatin-C-based estimates disagree.8
The Cystatin C Test with eGFR provides a cystatin-C-based estimate. The Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C uses both markers. Creatinine-to-cystatin-C ratios are being studied as markers of muscle mass and frailty, but they do not yet have a universally accepted direct-to-consumer threshold.
Hormone interpretation is relational, but not every mathematically possible hormone ratio is clinically validated.
ARR = Aldosterone ÷ Renin
The aldosterone-to-renin ratio is a recognized screening tool for primary aldosteronism, an endocrine cause of hypertension. Its interpretation depends on whether renin is measured as plasma renin activity or direct renin concentration, the aldosterone assay, units, potassium level, sodium intake, posture, time of collection, and medications.
The Endocrine Society provides assay-specific guidance and notes that an ARR above 20 may be suggestive when aldosterone is reported in ng/dL and plasma renin activity in ng/mL/hour—but only when renin is suppressed and aldosterone is sufficiently elevated. Local laboratory cutoffs and clinician-directed preparation should take priority.10
The Aldosterone and Plasma Renin Activity Ratio Test supplies the paired measurements. Do not stop blood-pressure medicines to prepare for ARR testing unless the prescribing clinician directs you to do so.
FAI = [Total testosterone (nmol/L) × 100] ÷ SHBG (nmol/L)
The free androgen index may help assess androgen excess in some women when total testosterone is difficult to interpret because sex hormone-binding globulin, or SHBG, is unusually high or low. It is less dependable for diagnosing testosterone deficiency in men. Male hypogonadism requires compatible symptoms plus consistently low testosterone results, usually confirmed with repeat morning testing.11
Minerals interact, but current guidance generally favors interpreting the individual values and the broader clinical setting rather than applying a universal ratio cutoff.
Calcium-phosphate product = Calcium × Phosphate
This product was historically used in advanced chronic kidney disease and dialysis care. Current kidney mineral-and-bone guidance emphasizes serial calcium, phosphate, and parathyroid hormone results considered together, rather than treating one universal calcium-phosphate product as an isolated target.14
Dividing 1,25-dihydroxyvitamin D by 25-hydroxyvitamin D has been studied in granulomatous disease, lymphoma, and kidney disorders. It is not the standard test for vitamin D status. The NIH Office of Dietary Supplements identifies serum 25-hydroxyvitamin D as the main indicator of vitamin D status; 1,25-dihydroxyvitamin D is tightly regulated and may remain normal until deficiency is severe.15
A serum sodium-to-potassium ratio does not diagnose adrenal insufficiency or aldosterone excess. Abnormal sodium and potassium values warrant evaluation of the individual results, medications, fluid status, kidney function, glucose, acid-base status, and endocrine context. When primary aldosteronism is suspected, ARR—not serum sodium divided by potassium—is the validated ratio.
Transferrin saturation = (Serum iron ÷ TIBC) × 100
Transferrin saturation, or TSAT, estimates how much of the blood’s iron-transport capacity is occupied.
Liver guidance recommends beginning suspected iron-overload evaluation with TSAT and ferritin and uses a TSAT threshold of at least 45% to guide further assessment.16 The Ferritin, Iron and Total Iron Binding Capacity Panel reports ferritin, iron, TIBC, and percent saturation.
A copper-to-zinc ratio has been associated with inflammation, nutritional status, and outcomes in observational research. It is not a standardized diagnostic test. Serum copper can rise with inflammation or estrogen exposure, while zinc can fall during acute illness. Supplementing zinc solely to change this ratio could obscure the underlying reason for the result.
Formulas that subtract ceruloplasmin-bound copper from total copper are sometimes used in Wilson disease evaluation. Their accuracy depends heavily on assay methods and they should be interpreted in a specialist workup that may include ceruloplasmin, 24-hour urine copper, eye examination, liver assessment, and genetic testing.
Percent-free PSA = (Free PSA ÷ Total PSA) × 100
The percentage of PSA circulating in an unbound form can help refine risk when total PSA is in a borderline range. A lower percentage is generally associated with a higher probability of prostate cancer, but it does not confirm cancer.
The American Cancer Society notes that clinicians differ in the exact cutoff used and that interpretation depends on total PSA and the complete clinical picture.17 The PSA Free and Total Test provides total PSA, free PSA, and the calculated percentage.
PSA density = Total PSA (ng/mL) ÷ Prostate volume (cc)
PSA density adjusts total PSA for gland size. It requires prostate volume from ultrasound or MRI and is therefore not a blood-only calculation. It can be helpful in urologic decision-making, particularly when MRI findings are uncertain.
PSA velocity describes the rate of change per year, while PSA doubling time estimates how quickly the PSA value doubles. Both require several reliable measurements over time.
Urology guidance states that PSA velocity should not be used as the sole reason for secondary biomarker testing, imaging, or biopsy. Infection, urinary retention, ejaculation, cycling, instrumentation, and assay variation can all affect PSA trends.18
The most useful testing strategy is based on the health question—not on ordering every possible ratio.
| Ulta Lab Tests option | What it measures | Why it may be relevant | Important limitations |
|---|---|---|---|
| Lipid Panel Test with Ratios | Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, and reported ratios | Provides the components for cholesterol/HDL, LDL/HDL, and TG/HDL interpretation | Ratios do not replace absolute lipids or overall cardiovascular risk assessment |
| Apolipoprotein A1 and B Test | ApoA1 and ApoB | Can add particle-related context when standard lipids are discordant | Not necessary for every person; ApoB interpretation depends on overall risk |
| Complete Blood Count with Differential and Platelets | Red and white blood cells, differential counts, RDW, and platelets | Supplies components for NLR, PLR, SII, APRI, and FIB-4 | Acute illness, medications, pregnancy, and hematologic conditions can alter counts |
| Comprehensive Metabolic Panel Test | AST, ALT, albumin, bilirubin, BUN, creatinine, electrolytes, glucose, and other markers | Supports liver, kidney, metabolic, and selected protein-derived ratios | A CMP does not include every needed component, such as platelets or CRP |
| Kidney Profile | Creatinine/eGFR and urine albumin-to-creatinine ratio | Combines the two central axes of chronic kidney disease risk assessment | Abnormal findings commonly require confirmation and clinical review |
| Albumin Random Urine Test with Creatinine | Urine albumin and urine creatinine | Provides uACR for albuminuria assessment | Exercise, infection, blood, and temporary physiological stress can affect the result |
| Cystatin C Test with eGFR | Cystatin C and cystatin-C-based eGFR | May add filtration information when creatinine is affected by muscle mass or other factors | Cystatin C also has non-kidney influences |
| Estimated Glomerular Filtration Rate (eGFR) with Creatinine and Cystatin C | Creatinine, cystatin C, and combined eGFR | Aligns with the preference for a combined equation when cystatin C is available | No estimating equation is perfect in every clinical condition |
| hs-CRP Test | Low concentrations of C-reactive protein | May provide cardiovascular or inflammatory context | Infection, injury, and other inflammation can raise hs-CRP |
| Ferritin, Iron and Total Iron Binding Capacity Panel | Ferritin, serum iron, TIBC, and percent saturation | Evaluates iron storage and transport together | Ferritin can rise during inflammation and liver disease |
| Aldosterone and Plasma Renin Activity Ratio Test | Aldosterone, plasma renin activity, and ARR | Supports clinician-directed screening for primary aldosteronism | Preparation, potassium, posture, sodium intake, and medications can change results |
| PSA Free and Total Test | Total PSA, free PSA, and percent-free PSA | Adds context when total PSA is borderline or changing | Does not diagnose cancer; recent prostate irritation can affect results |
Choose tests that match the primary health question:
Advanced testing may be useful when routine results do not fully explain risk:
A comprehensive approach may combine blood counts, metabolic testing, lipid testing, glucose-regulation markers, kidney testing, and targeted specialty tests. Comprehensive does not mean ordering every ratio. Testing is most useful when each result could reasonably change the questions discussed with a clinician.
The repeat interval depends on why the test was ordered, the magnitude of the result, recent illness, treatment changes, and the person’s underlying risk. Examples include:
A discussion about relevant lab testing may be appropriate when:
Testing without a defined question can increase the chance of incidental findings, unnecessary worry, and difficult-to-interpret results.
A laboratory reference interval usually describes values found in a defined reference population using that laboratory’s method. It does not guarantee perfect health inside the range or establish disease outside it.
Many biomarker ratios do not have standardized reference intervals. A research paper’s “optimal cutoff” may be the value that best separated two groups in that particular study—not a universal boundary for individual care.
For any abnormal ratio, examine three possibilities:
A falling AST-to-ALT ratio, for example, is not automatically improvement if both enzymes rose substantially. A lower TG-to-HDL ratio may reflect lower triglycerides, higher HDL-C, or both, and those changes may not carry identical meaning.
Particular caution is needed with:
Results can vary with age, sex, menstrual cycle, pregnancy, menopause, fasting status, hydration, time of day, body position, recent exercise, acute infection, injury, surgery, alcohol use, medications, supplements, muscle mass, and laboratory methodology.
An abnormal result may need confirmation after a temporary influence has resolved. A normal result may still require follow-up when symptoms, history, examination findings, or imaging suggest a health concern.
Ulta Lab Tests allows patients to order many relevant laboratory tests directly online where available. Prices are displayed before ordering, insurance is not required for direct-access purchases, and HSA or FSA payment may be available for eligible testing.
Testing is performed through established laboratory networks such as Quest Diagnostics where applicable, and results are delivered through a secure online account. Patients can then use those results to prepare more informed questions for their healthcare provider. Learn more on the How It Works page.
Direct access improves access to information; it does not make every test appropriate for every person or replace professional interpretation.
Review verified testing options, preparation instructions, and current pricing directly at Ulta Lab Tests.
Blood biomarker ratios compare two laboratory values or combine several values in one calculated score. Examples include LDL-to-HDL cholesterol, neutrophil-to-lymphocyte ratio, AST-to-ALT ratio, FIB-4, and transferrin saturation. Ratios can reveal balance or discordance between biological processes, but they must be interpreted alongside the original component results and the person’s clinical context.
The most useful ratio depends on the health question. uACR is central to kidney-risk assessment. FIB-4 helps triage liver-fibrosis risk in appropriate adults. APRI has a defined role in chronic hepatitis B settings. ARR supports screening for primary aldosteronism. Transferrin saturation evaluates iron transport, while percent-free PSA can add context to a borderline total PSA.
No. A ratio may be high because its numerator increased, its denominator decreased, or both. Some ratios also have U-shaped relationships in which very low and very high values can be relevant. Others lack validated high or low boundaries. The result should be compared with the individual components, laboratory units, prior trends, symptoms, and relevant clinical guidance.
No. A higher TG-to-HDL ratio is associated with insulin resistance and metabolic risk in many populations, but it is not a diagnostic test. Proposed thresholds differ by sex, age, ethnicity, weight, fasting status, and unit system. The Glucose Test, A1c Test, blood pressure, waist measurement, medical history, and sometimes additional testing provide a more complete assessment.
A high FIB-4 score means the combination of age, AST, ALT, and platelet count is associated with a greater likelihood of advanced liver fibrosis in the population for which the score was validated. It does not prove fibrosis or identify its cause. Values above 1.3 often prompt secondary assessment, while values above 2.67 increase concern in many adults with suspected metabolic liver disease.
uACR measures urine albumin relative to urine creatinine, helping account for how concentrated or dilute a spot urine sample is. A result below 30 mg/g is generally A1, 30–300 mg/g is A2, and above 300 mg/g is A3. Temporary factors can raise albumin, so an unexpected result usually needs confirmation and review with eGFR.
NLR can reflect a shift in immune-cell balance and has been associated with infection, physiological stress, inflammatory disease, surgery, and cancer outcomes. However, it is nonspecific and has no universal cutoff for general outpatient screening. An elevated NLR should be interpreted with the absolute cell counts, symptoms, medication use, recent illness, and other laboratory findings.
Simple ratios can be calculated when the units and formula are compatible. Composite scores such as FIB-4 and APRI require specific units, and some ratios such as uACR involve laboratory unit conversions. ARR is especially sensitive to assay type and units. A calculator may produce the arithmetic correctly while still producing a clinically inappropriate interpretation.
Through Ulta Lab Tests, patients can order many component tests directly online where available, including the Lipid Panel Test with Ratios, Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel Test, Kidney Profile, iron studies, cystatin C, hs-CRP, and PSA testing. Some tests, particularly ARR and specialty hormone testing, have complex preparation and interpretation requirements.
Repeat timing depends on the ratio, why it was measured, how abnormal it was, and whether a temporary factor may have influenced the components. An elevated uACR may be repeated within three to six months, while lipid, liver, hormone, or PSA follow-up follows different schedules. Use comparable preparation, timing, and laboratory methods whenever possible.
Ask whether the ratio is validated for your situation, whether the correct units were used, which component drove the change, and whether recent illness, exercise, medications, or supplements could have affected it. Also ask whether repeat testing, another biomarker, imaging, or specialist evaluation would add useful information before making health decisions.
Blood biomarker ratios can transform isolated laboratory numbers into a more connected picture of cardiovascular, metabolic, immune, liver, kidney, endocrine, iron, mineral, and prostate health. Their value comes from showing relationships—but that same feature creates important limitations. A ratio can change because either component changes, and many popular online cutoffs are not universally validated.
The most useful blood biomarker ratios are those chosen for a defined health question, calculated with the correct formula and units, and interpreted alongside individual results, trends, symptoms, history, and appropriate clinical guidance.
Ulta Lab Tests provides direct online access to many of the relevant component tests where available, with transparent pricing and secure online results. Explore relevant lab tests at UltaLabTests.com, and review your findings with a qualified healthcare provider before drawing conclusions or making health decisions.
Blood biomarker ratios compare two or more laboratory measurements to show physiological balance, relative excess, filtration, transport, inflammation, or disease probability. They can add important context to individual results, but they are not diagnoses and must be interpreted using the correct units, formula, clinical setting, and component values.
Related lab tests: Lipid Panel Test with Ratios, Apolipoprotein A1 and B Test, Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel Test, Kidney Profile, Albumin Random Urine Test with Creatinine, Cystatin C Test with eGFR, hs-CRP Test, Ferritin, Iron and Total Iron Binding Capacity Panel, Aldosterone and Plasma Renin Activity Ratio Test, and PSA Free and Total Test.
Ulta Lab Tests helps patients access many relevant laboratory tests directly online where available, with transparent pricing and secure online results.
Lab testing is informational and should be reviewed with a qualified healthcare professional.
These tests supply the principal values used for cholesterol-to-HDL, LDL-to-HDL, triglyceride-to-HDL, and ApoB-to-ApoA1 interpretation, while glucose and A1c provide additional metabolic context.
The CBC provides the cell counts used in ratios such as NLR and PLR and supplies platelet counts for APRI and FIB-4. The CMP supplies AST, ALT, albumin, bilirubin, BUN, creatinine, electrolytes, and other chemistry measurements.
These options cover creatinine-based filtration, urine albumin-to-creatinine ratio, cystatin C, and combined creatinine–cystatin C kidney-function assessment.
The aldosterone-renin test directly measures the components needed for ARR interpretation. The TSH and Free T4 test supports standard thyroid-function assessment rather than relying on a nonstandard thyroid ratio alone.
This panel includes ferritin, serum iron, TIBC, and percent iron saturation, providing the measurements needed to evaluate iron storage and transferrin saturation together.
This test provides total PSA, free PSA, and the percentage of free PSA needed for percent-free-PSA interpretation.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
